Health Condition 1: J985- Diseases of mediastinum, not elsewhere classified
Conditions
Interventions
Intervention1: Intranasal Dexmedetomidine: Intranasal Dexmedetomidine as a bolus sedative given over 10 minutes via nasal atomizer
Control Intervention1: Intravenous Dexmedetomidine: Intravenous Dexme
Sponsors
AIIMS Mangalagiri
Eligibility
Inclusion criteria
Inclusion criteria: 1. Age more than 18 years both male and female 2. Referred for EBUS-TBNA from mediastinal and/or hilar lymph nodes visible on thoracic CT scans 3. American Society of Anesthesiologists physical status I or II
Exclusion criteria
Exclusion criteria: 1. Patients with hemodynamic instability (hypotension, respiratory failure, arrhythmia, or recent acute coronary events) 2. Participants with baseline heart rate less than 50 beats per minute. 3. Any neuropsychiatric illness 4. Documented coagulopathy 5. Nasal obstruction, active rhinitis, sinusitis, and nasal polyposis 4. Known allergy to dexmedetomidine, midazolam, fentanyl, or lignocaine 5. Pregnant women or breastfeeding individuals 6. Patients undergoing a repeat EBUS-TBNA procedure 7. Failure to provide informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Patient comfort VAS Timepoint: One Hour after the procedure | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Physician comfort VAS 2. Total cumulative rescue dose of fentanyl ( g/kg) & midazolam (mg/kg) administered 3. Safety outcomes proportion of subjects developing hypotension, bradycardia, desaturation, airway intervention, or need to stop dexmedetomidine infusionTimepoint: Five minutes after the procedure | — |
Countries
India
Contacts
Public ContactSwetha R
AIIMS Mangalagiri
Outcome results
None listed